A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Timeline

Start

2018-10-10

Primary completion

2024-05-29

Completion

2024-05-29

Publications

• Di Caro V, Cho E, Thiel J, Lizama BN, Koel-Simmelink MJA, Pandey K, Duong D, Seyfried NT, Grundman M, Teunissen CE, Zetterberg H, Blennow K, Caggiano AO, Hamby ME. Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease. Alzheimers Res Ther. 2026 Apr 6;18(1):112. doi: 10.1186/s13195-026-02025-4.
• Vijverberg EGB, Scharre DW, Woodward M, Catalano S, Hamby ME, Grundman M, Morgan RE, Iaci J, Devins T, Caggiano AO. Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2026 May;111(2):897-908. doi: 10.1177/13872877261437145. Epub 2026 Apr 3.
• Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME. CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease. Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21.
• Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, Di Caro V, Ping L, Blennow K, Zetterberg H, Lah J, Levey AI, Grundman M, Caggiano AO, Seyfried NT, Hamby ME. An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease. Neurobiol Dis. 2024 Sep;199:106575. doi: 10.1016/j.nbd.2024.106575. Epub 2024 Jun 22.

Drugs

Indications

No indication recorded.